Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Inflamm Bowel Dis. 2017 Jan;23(1):14–22. doi: 10.1097/MIB.0000000000000907

Figure 3.

Figure 3

Industry sponsored interventional phase 2 and phase 3 studies in CD and UC in the US between 01/01/2005-01/01/2015 as listed on ClinicalTrials.gov. Only studies in adult patients with the following known statuses were counted: recruitment, completed, (with or without results), terminated with results. Trials evaluating the efficacy of mesalamine products in UC were excluded from the analyses.